1 / 29

Rubella and Rubella Vaccine

Rubella and Rubella Vaccine. Epidemiology and Prevention of Vaccine-Preventable Diseases National Immunization Program Centers for Disease Control and Prevention. Revised March 2002. Rubella. From Latin meaning "little red" Discovered in 18th century - thought to be variant of measles

cain
Download Presentation

Rubella and Rubella Vaccine

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Rubella and Rubella Vaccine Epidemiology and Prevention of Vaccine-Preventable Diseases National Immunization Program Centers for Disease Control and Prevention Revised March 2002

  2. Rubella • From Latin meaning "little red" • Discovered in 18th century - thought to be variant of measles • First described as distinct clinical entity in German literature • Congenital rubella syndrome described by Gregg in 1941

  3. Rubella Virus • Togavirus • RNA virus • One antigenic type • Rapidly inactivated by chemical agents, low pH, heat and ultraviolet light

  4. Rubella Pathogenesis • Respiratory transmission of virus • Replication in nasopharynx and regional lymph nodes • Viremia 5-7 days after exposure with spread to tissues • Placenta and fetus infected during viremia

  5. Rubella Clinical Features • Incubation period 14 days (range 12-23 days) • Prodrome of low grade fever • Lymphadenopathy in second week • Maculopapular rash 14-17 days after exposure

  6. Rubella Complications rare up to 70% 1/3000 cases 1/5,000+ cases rare rare Arthralgia or arthritis children adult female Thrombocytopenic purpura Encephalitis Neuritis Orchitis

  7. Congenital Rubella Syndrome • Infection may affect all organs • May lead to fetal death or premature delivery • Severity of damage to fetus depends on gestational age • Up to 85% of infants affected if infected during first trimester

  8. Congenital Rubella Syndrome • Deafness • Cataracts • Heart defects • Microcephaly • Mental retardation • Bone alterations • Liver and spleen damage

  9. Epidemic Rubella – United States, 1964-1965 • 12.5 million rubella cases • 2,000 encephalitis cases • 11,250 abortions (surgical/spontaneous) • 2,100 neonatal deaths • 20,000 CRS cases • Deaf - 11,600 • Blind - 3,580 • Mentally retarded - 1,800

  10. Rubella Laboratory Diagnosis • Isolation of rubella virus from clinical specimen (e.g., nasopharynx, urine) • Significant rise in rubella IgG by any standard serologic assay (e.g., enzyme immunoassay) • Positive serologic test for rubella IgM antibody

  11. Rubella Epidemiology • Reservoir Human • Transmission Respiratory Subclinical cases may transmit • Temporal pattern Peak in late winter and spring • Communicability 7 days before to 5-7 days after rash onset Infants with CRS may shed virus for a year or more

  12. Rubella - United States, 1966-2001* *2001 provisional data

  13. Rubella - United States, 1980-2001* *2001 provisional data

  14. Rubella - United States, 1980-2000Age Distribution of Reported Cases

  15. Rubella and CRS in the United States, 1990s • Most reported rubella in the U.S. since the mid-1990s has occurred among foreign-born Hispanic adults • Rubella outbreaks have occurred in workplaces where most employees are foreign-born • 83% of CRS since 1997 occurred in children of unvaccinated women born to Hispanic women, most born in Latin America

  16. Rubella Case Definition • Acute onset of generalized maculopapular rash, and • Temperature of >37.2 C (>99 F), if measured, and • Arthritis/arthralgia or lymphadenopathy or conjunctivitis

  17. Rubella Outbreak Control Guidelines • Laboratory diagnosis of rubella and CRS • Step-by-step guidelines on evaluation and management of outbreak • Rubella prevention and control among women of childbearing age • Rubella and CRS surveillance MMWR 2001;50(RR-12)

  18. Trade Name Cendevax Rubelogen Meruvax Meruvax II Licensure 1969 1969 1969 1979 Vaccine GMK-3:RK53 HPV-77:DK12 HPV-77:DE5 RA 27/3* Rubella Vaccine *Only vaccine currently licensed in U.S.

  19. Rubella Vaccine • Composition Live virus (RA 27/3 strain) • Efficacy 95% (Range, 90%-97%) • Duration ofImmunity Lifelong • Schedule 1 Dose • Should be administered with measles and mumps as MMR

  20. Rubella Vaccine (MMR) Indications • All infants >12 months of age • Susceptible adolescents and adults without documented evidence of rubella immunity • Emphasis on non-pregnant women of childbearing age, particularly those born outside the U.S.

  21. Rubella Immunity • Documentation of one dose of rubella-containing vaccine on or after the first birthday • Serologic evidence of immunity • Birth before 1957 (except women of childbearing age)

  22. Rubella Immunity • Birth before 1957 is not acceptable evidence of rubella immunity for women who might become pregnant • Only serology or documented vaccination should be accepted

  23. MMR Adverse Reactions • Fever 5%-15% • Rash 5% • Joint symptoms 25% • Thrombocytopenia <1/30,000 doses • Parotitis rare • Deafness rare • Encephalopathy <1/1,000,000 doses

  24. Rubella Vaccine Arthropathy • Acute joint symptoms in about 25% of susceptable adult women • Frank arthritis occurs in about 10% • Rare reports of chronic or persistent symptoms • Population-based studies have not confirmed association

  25. MMR VaccineContraindications and Precautions • Severe allergic reaction to prior dose or vaccine component • Pregnancy • Immunosuppression • Moderate or severe acute illness • Recent blood product

  26. Vaccination of Women of Childbearing Age • Ask if pregnant or likely to become so in next 4 weeks • Exclude those who say "yes" • For others • Explain theoretical risks • Vaccinate

  27. Vaccination in Pregnancy Study 1971-1989 • 321 women vaccinated • 324 live births • No observed CRS • 95% confidence limits 0%-1.2%

  28. Rubella VaccineRecommendations for Increasing Coverage • Continued routine vaccination of children at age >12 months with vaccination required for school entry • Screen and vaccinate susceptible persons • health care workers • college entry • prenatal with postpartum vaccination • other health care visits • workplace

  29. National Immunization Program • Hotline 800.232.2522 • Email nipinfo@cdc.gov • Website www.cdc.gov/nip

More Related